Sight Sciences (NASDAQ:SGHT) 주식

SIGHT SCIENCES INC

Sight Sciences

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Sight Sciences Inc

Mueller Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLI#NYSE">MLI</a>) has outperformed the market over the past 10 years by 5.02% on an annualized basis producing an average annual return of 15.34%. Currently, Mueller Industries has a market capitalization of $8.17 billion. 
Buying $1000 In MLI: If an investor had bought $1000 of MLI stock 10 years ago, it would be worth $4,130.98 today based on a price of $73.80 for MLI at the time of writing.
<h3>Mueller Industries's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746650717_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much $1000 Invested In Mueller Industries 10 Years Ago Would Be Worth Today

Chardan Research initiated coverage on Wednesday of Bright Minds Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>), an <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">epilepsy drug developer</a>.
The company&#8217;s lead product, BMB-101, is a novel scaffold 5-HT2C Gq-protein biased agonist developed using structure-based drug design.
The drug candidate is designed for the chronic treatment of neurological disorders where tolerance and drug resistance are common issues.
Biased agonism at the 5-HT2C receptor is one of its key features and adds another layer of functional selectivity within a well-validated target.
In preclinical studies, BMB-101 has demonstrated efficacy in animal models of Dravet Syndrome and numerous models of generalized seizures.
The company&#8217;s BREAKTHROUGH Phase 2 study is an open-label trial evaluating the safety, tolerability, and efficacy of BMB-101 in adult patients with classic Absence Epilepsy and Developmental<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45036333/bright-minds-biosciences-to-host-virtual-r-d-day-on-may-20-2025-program-highlights-include-an-over" rel="noreferrer noopener"> and Epileptic Encephalopathy (DEE)</a>.
&#8220;We believe BMB-101 has a decent chance of working in treating epilepsy, and it could be differentiated vs other 5-HT2C agonists,&#8221; analyst Rudy Li writes.
The Chardan analyst projects over $1 billion combined peak sales in DEE and absence epilepsy but acknowledges that, given the limited data available, this remains a high-risk, high-reward play.
Analyst Li initiated coverage with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/DRUG/analyst-ratings" rel="noreferrer noopener">price target of $80</a>.
Chardan says the stock was not under investors&#8217; radar until Denmark-based&nbsp;H. Lundbeck A/S acquired Longboard Pharmaceuticals for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41313129/why-is-epilepsy-focused-longboard-pharmaceuticals-stock-trading-higher-on-monday" rel="noreferrer noopener">$60.00 per share in cash</a> last October for its 5-HT2C agonist bexicaserin, which has a similar binding profile to the company&#8217;s BMB-101.
While the stock has moved up significantly following the news, that analyst sees an interesting story even at the current valuation of over $200 million in market cap, as per <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">data from Benzinga Pro</a>.
Chardan views Bright Minds Biosciences as a high-risk, high-reward play despite the partially validated mechanism of action.
Price Action: DRUG stock is up 4.84% at $30.43&nbsp;at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45257358/animal-health-elanco-sees-momentum-building-despite-challenging-market-backdrop-q1-earnings-beat-estimates" target="_blank" rel="noreferrer noopener">Animal Health Elanco Chirps A Solid Quarter Tempered By Soft Q2 EPS Guide</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Health Care

Initiation

Analyst Ratings

Movers

General

DRUG

Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 52.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed up 35.29% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 16.67% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 13.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 9.09% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 7.77% at $0.43</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed up 4.24% at $0.65</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed down 20.79% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 19.78% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 16.67% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 16.25% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 13.26% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed down 9.43% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Indus</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed down 9.42% at $6.02</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed down 9.09% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 8.73% at $0.14</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed down 7.26% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed down 6.72% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 4.17% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed down 4.17% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 3.69% at $0.05</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

BBRRF

CBDY

CLSH

CNBX

CNTMF

CWBHF

CXXIF

FFNTF

GBHPF

GNLN

GTBIF

ITHUF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LMLLF

MRMD

RMHB

RSSFF

SOLCF

TGIFF

UGRO

Cannabis Stock Movers For May 7, 2025

Digi Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGII#NASDAQ">DGII</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.48 by 6.25 percent. This is a 4.08 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $104.50 million which beat the analyst consensus estimate of $104.08 million by 0.40 percent. This is a 2.97 percent decrease over sales of $107.70 million the same period last year.

Earnings

Earnings Beats

DGII

Digi Intl Q2 Adj. EPS $0.51 Beats $0.48 Estimate, Sales $104.50M Beat $104.08M Estimate

OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) raises FY2025 sales outlook from $235.00 million-$242.00 million to $236.00 million-$242.00 million vs $238.83 million estimate.

Guidance

KIDS

OrthoPediatrics Raises FY2025 Sales Guidance from $235.00M-$242.00M to $236.00M-$242.00M vs $238.83M Est

Tutor Perini (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPC#NYSE">TPC</a>) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $0.10 by 430 percent. This is a 76.67 percent increase over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $1.25 billion which beat the analyst consensus estimate of $1.06 billion by 17.43 percent. This is a 18.78 percent increase over sales of $1.05 billion the same period last year.

Tutor Perini Q1 EPS $0.53 Beats $0.10 Estimate, Sales $1.25B Beat $1.06B Estimate

Sitio Royalties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STR#NYSE">STR</a>) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.05 by 160 percent. This is a 30 percent increase over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $163.51 million which beat the analyst consensus estimate of $137.17 million by 19.21 percent. This is a 8.01 percent increase over sales of $151.39 million the same period last year.

Sitio Royalties Q1 EPS $0.13 Beats $0.05 Estimate, Sales $163.51M Beat $137.17M Estimate

Open Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) reported quarterly earnings of $0.01 per share which met the analyst consensus estimate. This is a 75 percent decrease over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $24.39 million which missed the analyst consensus estimate of $24.62 million by 0.93 percent. This is a 20.66 percent decrease over sales of $30.75 million the same period last year.

Earnings Misses

LPRO

Open Lending Q1 EPS $0.01, Inline, Sales $24.39M Miss $24.62M Estimate

Sezzle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) raises FY2025 GAAP EPS guidance from $2.21 to $3.25 vs $1.29 analyst estimate..

SEZL

Sezzle Raises FY2025 GAAP EPS Guidance from $2.21 to $3.25 vs $1.29 Est

Sezzle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) raises FY2025 Adj EPS guidance from $2.21 to $3.25 vs $1.29 analyst estimate. Raises FY2025 Sales growth Guidance from 25-30% to 60-65%.

Sezzle Raises FY2025 Adj EPS Guidance from $2.21 to $3.25 vs $1.29 Est; Raises FY2025 Sales growth Guidance from 25-30% to 60-65%.

Opendoor Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>) stock traded lower Wednesday after the company reported first-quarter earnings on Tuesday after <a href="https://www.benzinga.com//node/45238364">the market closed.</a>
What To Know: Opendoor reported a loss of nine cents per share, beating the consensus estimate of a 10 loss. In addition, the company reported sales of $1.15 billion, beating the consensus estimate of $1.06 billion, but representing a 2% year-over-year decrease.
Opendoor reported an inventory balance of $2.4 billion, representing 7,080 homes, a 26% increase from a year ago.
&#8220;We&#8217;ve spent the last decade building a modern real estate platform — designed to deliver simplicity, certainty, and a customer-first experience. We entered 2025 with a clear plan to drive toward profitability while strengthening our product experience and platform. Our&nbsp;first-quarter&nbsp;results reflect disciplined execution: we improved Adjusted EBITDA and sharply reduced Adjusted Net Losses,&#8221; said Carrie Wheeler, CEO of Opendoor.
Outlook: Opendoor sees second-quarter sales from $1.45 billion to $1.52 billion, versus the consensus estimate of $1.45 billion.
OPEN Price Action: Opendoor stock closed Wednesday 24.36% higher at 87 cents, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Related Link: • <a href="https://www.benzinga.com/25/05/45263841/disney-stock-is-surging-wednesday-heres-why">Disney Stock Is Surging Wednesday: Here&#8217;s Why</a>
Image: This illustration was generated using artificial intelligence via Midjourney.

OPEN

What's Going On With Opendoor Shares Wednesday?

CF Industries Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) reported quarterly earnings of $1.85 per share which beat the analyst consensus estimate of $1.44 by 28.47 percent. This is a 79.61 percent increase over earnings of $1.03 per share from the same period last year. The company reported quarterly sales of $1.66 billion which beat the analyst consensus estimate of $1.53 billion by 8.66 percent. This is a 13.13 percent increase over sales of $1.47 billion the same period last year.

CF Industries Holdings Q1 EPS $1.85 Beats $1.44 Estimate, Sales $1.66B Beat $1.53B Estimate

Jimmy Donaldson—better known as MrBeast—earned $85 million in 2024, <a href="https://www.forbes.com/profile/mrbeast/">according to Forbes</a>, and commands 391 million subscribers. But the world's richest YouTuber says his fame comes at a price most people would never want to pay.
"I don't think most people would be happy living my life," Donaldson said in <a href="https://youtu.be/FjrJ2DJN_pA?si=L_FHj48GC7v_ZVnA">February on "The Diary of a CEO" podcast.</a> "They would be miserable—because you're just working all the time."
At 26, Donaldson runs not only his YouTube empire <a href="https://www.benzinga.com/news/25/04/44794639/ironically-because-of-all-the-new-tariffs-its-now-way-cheaper-to-make-our-chocolate-bars-outside-the-us-says-mrbeast">but also Feastables chocolate</a>, Beast Burger, and multiple philanthropic ventures. His schedule often includes flying hundreds of days a year, surviving weeks without sleep, and managing what he calls a "robotic" life.
"There's a reason no one makes videos like me," he said. "No one wants to live the life I live. <a href="https://www.benzinga.com/personal-finance/25/04/44968223/now-millions-hate-me-mrbeast-says-article-twisted-his-words-falsely-quoted-him-as-saying-lifes-easier-when-youre-broke">They'd be miserable</a>."
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
Even things he enjoys—like strategy board games—get pushed aside. "I look at the schedule and think, ‘Maybe I can do that in four days,' but I can't. I have to film. I have to run businesses. I have to network."
Donaldson compared his life to being caged. "Sometimes those emotions take over. I'm like a zoo animal. I don't have free will."&nbsp;
He added, "I don't think most people would be happy living my life."&nbsp;
When asked if he's personally happy, he explained it really depends on the day. His baseline for the year is more "unhappy than happy."
Trending: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
But he says he's been able to work though these though, this is the life he chose and the price he has to pay.&nbsp;
This struggle isn't unique to him. Host Steven Bartlett drew a parallel to Elon Musk, who once told The Joe Rogan Experience that <a href="https://www.benzinga.com/personal-finance/24/04/38148624/elon-musk-says-people-may-think-theyd-want-to-be-him-but-really-wouldnt-people-dont-understand-h">no one would want to be inside his mind.</a> Donaldson agreed.&nbsp;
Yet, he views the misery as a competitive advantage. "What you feel right now is why no one else does what you do. If you push through, that's why no one will ever be who you are."
Even as his businesses rake in millions, Donaldson said he keeps only what he needs personally. "Money is fuel to grow a business. That's all."
The harshest part? <a href="https://www.benzinga.com/personal-finance/25/04/45056963/mrbeast-says-his-2-worst-performing-videos-this-year-were-the-ones-where-he-helped-people-id-get-way-more-views-if-i-didnt-do-charity">Even philanthropy sparks backlash</a>. "The more good you do, the more people think you're secretly evil," he said. "If you want to be liked, I actually don't recommend you help people."
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
For Donaldson, the grind continues. "I think we'll hit a billion subscribers. And I don't think anyone will be anywhere near close."
A lot of people imagine that <a href="https://www.benzinga.com/personal-finance/24/02/36960367/average-person-believes-financial-happiness-comes-with-a-1-2-million-price-tag-revealing-money-c">money and fame guarantee happiness</a>, especially in the world of content creation where making videos looks like the dream job. But as Donaldson points out, that dream can quickly turn into a relentless grind. The pressure to perform, the constant demands, and the loss of personal freedom are realities most don't see. Even those at the very top often admit the spotlight comes with more unhappiness than joy.&nbsp;
Read Next:
<ul>
<li>Donald Trump just announced a $500 billion AI infrastructure deal — <a href="https://www.benzinga.com/money/seize-a-share-while-you-still-can-in-the-2-trillion-entertainment-market-with-elf-labs-at-just-2-25-share">here's how you can invest in the entertainment market's next big disruptor at $2.25 per share</a>.</li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

MrBeast Is The Richest YouTuber In The World, But Says 'I'm Like A Zoo Animal' With No Free Will — 'No One Wants To Live The Life I Live'

KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) raises FY2025 sales outlook from $38.00 million-$39.00 million to $38.50 million-$39.50 million vs $38.43 million estimate.

KRMD

KORU Medical Systems Raises FY2025 Sales Guidance from $38.00M-$39.00M to $38.50M-$39.50M vs $38.43M Est

SEMR

SEMrush Hldgs Affirms FY2025 Sales Guidance of $448.00M-$453.00M vs $447.68M Est

Nextdoor Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIND#NYSE">KIND</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 14.29 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $54.18 million which beat the analyst consensus estimate of $53.12 million by 1.98 percent. This is a 1.94 percent increase over sales of $53.15 million the same period last year.

KIND

Nextdoor Holdings Q1 EPS $(0.06) Beats $(0.07) Estimate, Sales $54.18M Beat $53.12M Estimate

OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.45) by 13.33 percent. This is a 30 percent decrease over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $52.41 million which beat the analyst consensus estimate of $51.68 million by 1.41 percent. This is a 17.29 percent increase over sales of $44.69 million the same period last year.

OrthoPediatrics Q1 Adj. EPS $(0.39) Beats $(0.45) Estimate, Sales $52.41M Beat $51.68M Estimate

Laird Superfood (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LSF#AMEX">LSF</a>) affirms FY2025 sales outlook from $51.60 million-$55.00 million to $51.60 million-$55.00 million vs $52.55 million estimate.

Laird Superfood Affirms FY2025 Sales Guidance of $51.60M-$55.00M vs $52.55M Est

KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) reported quarterly sales of $9.63 million which beat the analyst consensus estimate of $8.87 million by 8.62 percent. This is a 17.53 percent increase over sales of $8.20 million the same period last year.

KORU Medical Systems Q1 Sales $9.63M Beat $8.87M Estimate

Paycom Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) raises FY2025 sales outlook from $2.02 billion-$2.04 billion to $2.02 billion-$2.04 billion vs $2.02 billion estimate.

PAYC

Paycom Software Raises FY2025 Sales Guidance of $2.02B-$2.04B vs $2.02B Est

Press Releases

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2024 Financial Highlights

Sight Sciences to Present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day

Sight Sciences to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025

Sight Sciences to Present Comprehensive Clinical Data on the OMNI® Surgical System at the 2025 American Glaucoma Society Annual Meeting

Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance

Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th

Sight Sciences to Debut OMNI® Edge Surgical System at the 2025 ASCRS Annual Meeting, Expanding the OMNI Product Portfolio

Management

Sight Sciences Appoints Gary Burbach to its Board of Directors

Sight Sciences Announces the Release of its Sustainability Report

Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

BWXT

SGHT

Accuray

Anteris Technologies Global Corp. - Common Stock

Anteris Technologies

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

BrainsWay Ltd. - American Depositary Shares

BrainsWay

CVRx

Alpha Tau Medical

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Sight Sciences

뉴스

파트너 / 기고자

벤징가 글로벌